201 related articles for article (PubMed ID: 31469912)
21. Inflammatory cytokine levels and changes during omalizumab treatment in chronic spontaneous urticaria.
Hoşgören-Tekin S; Eyüboğlu İP; Akkiprik M; Giménez-Arnau AM; Salman A
Arch Dermatol Res; 2024 May; 316(6):261. PubMed ID: 38795119
[TBL] [Abstract][Full Text] [Related]
22. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
23. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
Cho YT; Fu KT; Yang CW; Chu CY
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
[No Abstract] [Full Text] [Related]
24. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review.
Gimenez-Arnau AM; Salman A; Podder I
Eur J Dermatol; 2024 Feb; 34(1):3-12. PubMed ID: 38557452
[TBL] [Abstract][Full Text] [Related]
25. Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.
Giménez-Arnau AM; Salman A
Drugs; 2020 Nov; 80(16):1617-1634. PubMed ID: 32857360
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab in the treatment of antihistamine-resistant chronic urticaria in adults.
Gómez-Vera J; Gutiérrez-Ávila SA; Acosta-Gutiérrez DN; López-Tiro JJ; Bedolla-Barajas M
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):204-6. PubMed ID: 27369651
[No Abstract] [Full Text] [Related]
27. IFN-γ/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy.
Grieco T; Porzia A; Paolino G; Chello C; Sernicola A; Faina V; Carnicelli G; Moliterni E; Mainiero F
Int J Dermatol; 2020 May; 59(5):590-594. PubMed ID: 32048727
[TBL] [Abstract][Full Text] [Related]
28. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial.
Maurer M; Schütz A; Weller K; Schoepke N; Peveling-Oberhag A; Staubach P; Müller S; Jakob T; Metz M
J Allergy Clin Immunol; 2017 Sep; 140(3):870-873.e5. PubMed ID: 28389391
[No Abstract] [Full Text] [Related]
29. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?
Asero R
Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):268-270. PubMed ID: 32191021
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.
Metz M; Vadasz Z; Kocatürk E; Giménez-Arnau AM
Clin Rev Allergy Immunol; 2020 Aug; 59(1):38-45. PubMed ID: 32418171
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
Belbezier A; Boccon-Gibod I; Bouillet L
Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
[No Abstract] [Full Text] [Related]
32. Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria.
Kulumbegov B; Chikovani T; Gotua M; Kikodze N; Magen E
Allergy Asthma Proc; 2023 Nov; 44(6):429-435. PubMed ID: 37919851
[No Abstract] [Full Text] [Related]
33. The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.
Bostan E; Zaid F; Karaduman A; Dogan S; Gulseren D; Yalici-Armagan B; Akdogan N; Ersoy-Evans S; Elcin G
J Cosmet Dermatol; 2021 Nov; 20(11):3369-3375. PubMed ID: 34599630
[TBL] [Abstract][Full Text] [Related]
34. The response to treatment in chronic spontaneous urticaria depends on how it is measured.
Weller K; Church MK; Metz M; Hawro T; Ohanyan T; Staubach P; Maurer M
J Allergy Clin Immunol Pract; 2019; 7(6):2055-2056.e4. PubMed ID: 30731179
[No Abstract] [Full Text] [Related]
35. New treatments for chronic urticaria.
Kolkhir P; Altrichter S; Munoz M; Hawro T; Maurer M
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):2-12. PubMed ID: 31446134
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
[TBL] [Abstract][Full Text] [Related]
37. Factors related to omalizumab resistance in chronic spontaneous urticaria.
Magen E; Chikovani T; Waitman DA; Kahan NR
Allergy Asthma Proc; 2019 Jul; 40(4):273-278. PubMed ID: 31262381
[No Abstract] [Full Text] [Related]
38. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Refractory Chronic Spontaneous Urticaria Treated With Omalizumab in an Adolescent With Crohn's Disease.
Barni S; Giovannini M; Liccioli G; Sarti L; Gissi A; Lionetti P; Mori F
Front Immunol; 2021; 12():635069. PubMed ID: 33737936
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab for chronic urticaria in children younger than 12 years.
Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
